GHK-CU, product photo

2 lab reports

PDF
99%
Purity
Tested
GHK-CU 100mg
Lab
Analiza Białek
Date
August 2026
Result
99% purity (111.71 mg measured)
Endotoxins
6.82 EU/vial
Order no.
Password

Tested independently, verifiable with the password directly at the lab.

Healing

GHK-CU

The copper tripeptide from human plasma. A research classic for collagen, skin and regenerative pathways.

Order

Unit price -
  • DHL with tracking
  • Discreet packaging

Also searched as: Kupferpeptid · Copper Peptide GHK

At a glance

GHK-CU by the numbers

The key figures from our lexicon.

Full lexicon entry
Class
Copper tripeptide

GHK-Cu

Frequency
Daily or every other day
Form
Lyophilised powder

reconstituted with BAC water

Sizes
50 to 100 mg

2 sizes in the shop

For research and educational purposes only. Values from the TPD lexicon, sources linked there.

Knowledge

Everything about GHK-CU

Description

GHK-Cu is a naturally occurring tripeptide composed of glycine, histidine and lysine, forming a complex with copper ions. The substance was originally isolated from human plasma in the early 1970s. Its concentration in the body declines with age, which is why GHK-Cu is established as a central compound in the field of anti-aging and skin regeneration.

Across more than five decades of research, GHK-Cu has demonstrated effects in preclinical and in vitro studies on a wide range of pathways: stimulation of collagen and glycosaminoglycan synthesis, modulation of metalloproteinases and their inhibitors, promotion of angiogenesis (formation of new blood vessels), antioxidant and anti-inflammatory activity as well as activation of genes involved in tissue repair.

In research models, measurable effects are observed at very low concentrations (1 to 10 nanomolar). GHK-Cu acts in vitro on dermal fibroblasts, keratinocytes and endothelial cells. In studies with topical application, improvements in skin density, elasticity and collagen I production were observed. Effects are also documented in research on lung tissue, bone, liver and gastric mucosa.

In recovery and anti-aging research, GHK-Cu is among the most intensively studied compounds. Due to sensitivity to carboxypeptidases, the substance is often used in stabilized formulations or in stack combinations.

You can order GHK-Cu in 10-vial packs at 50mg per vial.

This information is for research and educational purposes only. No medical recommendations.

Risks & Safety

GHK-Cu is considered well tolerated per study reports. Across more than five decades of research, a mild profile has been documented, particularly with topical and low-dose subcutaneous use.

Observed in research and user reports:

  • Injection site: mild redness, pressure or transient irritation at the injection site is the most common observation with subcutaneous use.
  • Copper component: as a copper-containing tripeptide, GHK-Cu can cause somewhat more pronounced local irritation at the injection site than pure peptide solutions. Very high or frequent dosing is associated in the literature with a theoretical concern of copper accumulation.
  • Circulation: isolated reports of brief fatigue or a feeling of warmth shortly after application.
  • No long-term data: robust long-term human studies and data on systemic use do not exist. The favorable safety profile rests primarily on in vitro models, topical studies and short-term anecdotal experience.

This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.

Studies

Good to have

What you need with it

Bacteriostatic water is added to your cart automatically. Syringes and swabs with one click.

automatic

Bacteriostatic water

Matched to your amount, price in the cart.

Insulin Syringes

10 pcs · 5.50 €

Alcohol Swabs

50 pcs · 10 €

How much water?

Units on the syringe for your vial size.

Open calculator →

FAQ

Frequently asked

Sources for every answer: lexicon entry

Still have a question?

Write to us, our team will help you.

Is GHK-Cu approved?

No, as of 26 October 2026 there is no approval. ClinicalTrials.gov lists no trial in phase 2 or phase 3. Only an early phase 1 trial with a serum of several peptides is running. ChEMBL lists GHK without a clinical phase.

What role does the copper play?

GHK binds copper about as tightly as the copper transport site of the blood protein albumin. In cell studies the peptide helped bring copper into cells.

What do the human studies show?

They are small and use gel or cream on the skin. In a randomised trial on diabetic foot ulcers a median 98.5 percent of the wound area closed with GHK-Cu gel, 60.8 percent with vehicle gel. After facial laser treatment a study with 13 people found no objective difference, only satisfaction was higher. Other cosmetic studies are small and mostly not listed in PubMed.

Are there studies on injection?

We found no controlled human studies with injection. In animal studies GHK-Cu was injected, for example into wound chambers under the skin of rats. Recent reviews call the clinical evidence sparse and see GHK-Cu as promising but unproven.

What does it mean that GHK changes more than 4,000 genes?

The figure comes from the Connectivity Map, a database of gene profiles from cell lines. About 31.2 percent of all genes measured changed by at least 50 percent; according to the review 59 percent were upregulated and 41 percent downregulated. In a lung study GHK reversed a gene pattern of tissue destruction this way. Whether the same happens in the body has not been measured.

Why is there less GHK with age?

According to a review, GHK in blood is about 200 ng/ml at age 20 and about 80 ng/ml at 60. The decline coincides with fading regeneration. No study has tested whether added GHK-Cu makes up for this decline.

Which side effects are known?

Systematic data are lacking. In skin cells GHK-Cu caused no irritation, while free copper salts at the same amount did. In the gel trial there were fewer infections than with vehicle gel. A review of peptides in sports medicine stresses that robust human safety data are missing for many of these substances.

Which trials are still running?

The registry only lists one early phase 1 trial: a serum with several peptides including GHK-Cu is applied to the skin of 48 planned participants, with the primary endpoint planned for October 2028. There are no results yet.

Comparisons

How it compares

Related

Related products